(S)-2-(3,4-DICHLOROPHENYL)-8-ETHYL-9-METHYL-4-PROPYL-4,5,7,8-TETRAHYDRO-1H-IMIDAZO-[2,1-I]-PURIN-5-ONE
Compound with spectra: 1 NMR
![(S)-2-(3,4-DICHLOROPHENYL)-8-ETHYL-9-METHYL-4-PROPYL-4,5,7,8-TETRAHYDRO-1H-IMIDAZO-[2,1-I]-PURIN-5-ONE](/api/compound/6Hxm2RRxZKK.png?ph=true&h=300&w=458 "(S)-2-(3,4-DICHLOROPHENYL)-8-ETHYL-9-METHYL-4-PROPYL-4,5,7,8-TETRAHYDRO-1H-IMIDAZO-[2,1-I]-PURIN-5-ONE")
| SpectraBase Compound ID | 6Hxm2RRxZKK |
|---|---|
| InChI | InChI=1S/C19H21Cl2N5O/c1-4-8-25-17-15(18-24(3)12(5-2)10-26(18)19(25)27)22-16(23-17)11-6-7-13(20)14(21)9-11/h6-7,9,12H,4-5,8,10H2,1-3H3 |
| InChIKey | GLEUCPCQVDHKJY-UHFFFAOYSA-N |
| Mol Weight | 406.32 g/mol |
| Molecular Formula | C19H21Cl2N5O |
| Exact Mass | 405.112316 g/mol |
| Copyright | Copyright © 2016-2025 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | CDCl3 |
(R)-4,9-DIMETHYL-8-ETHYL-2-(2,3,5-TRICHLOROPHENYL)-4,5,7,8-TETRAHYDRO-1H-IMIDAZO-[2,1-I]-PURIN-5-ONE
22,26-Epiminocholest-5-ene-3.beta.,16.beta.,23-triol
(1R,3R,4R,7R)-7-BENZYLOXY-1-(BENZOYLOXYMETHYL)-3-[3-(BENZYLOXYMETHYL)-THYMIN-1-YL]-2-OXA-5-AZABICYCLO-[2.2.1]-HEPTANE
3,9-Dimethoxy-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-6-benzyl-5,7(6H)-dione
TENUIFOLIN_B;3-BETA,11-BETA,15-BETA-TRIHYDROXY-ENT-KAUR-16-ENE
5.ALPHA.-ANDROSTANE-9,17.BETA.-DIOL-3-ONE-TRIMETHYLSILYL ETHER
8-(4-Chloranyl-2-cyclohexyl-phenoxy)-7-[(3,4-diethoxyphenyl)methyl]-1,3-dimethyl-purine-2,6-dione
9-Hydroxy-2,6,6-trimethyl-3a,4,11b,11c-tetrahydrochromeno[4,3-e]isoindole-1,3(2H,6H)-dione
17-(Cyclobutylmethyl)-3-methoxymorphinan-14-ol
Indeno[1,2-b]oxireno[c]pyridazin-9-ol, 9-ethyl-1a,2,3,9-tetrahydro-, (1a.alpha.,9.beta.,9aS*)-(.+-.)-
| Title | Journal or Book | Year |
|---|---|---|
| 2-Phenylimidazo[2,1-i]purin-5-ones Structure–Activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors | Bioorganic & Medicinal Chemistry | 2003 |